[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Swathy Chandrashekhar, MBBS\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100556601",false,"NCT06527222","A Study of Ranolazine in ALS","Ranolazine in ALS: Safety, and Effect on Cramps, Function and Quality of Life.","Inclusion Criteria:\n\n* 18 years or older\n* Diagnosed with clinically definite, possible, probably, or lab-supported probable ALS per revised El Escorial criteria\n* Breathing assessment called forced vital capacity (FVC) greater than or equal to 50%.\n* Able to swallow pills at the start of the study and expected to for the length of the study.\n* If on ALS modifying medications must be on a stable dose at least 30 days.\n* Experiencing 4 or more cramps per week during a 2-week screening period.\n\nExclusion Criteria:\n\n* Disease duration \\\u003C 5 years\n* Tracheostomy invasive ventilation, or noninvasive ventilation of more than 12 hours\u002Fday\n* Pregnant or lactating, adults unable to consent, and prisoners\n* Taking ranolazine or investigational drug or has received an investigational drug within 30 days (or 5 half-lives for drugs, whichever is longer) prior to screening\n* Medically uncontrolled comorbidities (heart, liver, kidney disease)\n* Baseline QTc interval prolongation \\>450 ms for men\u002F \\>470 ms for women, history of long QT syndrome, or medications which prolong the QT interval\n* Participation in an experimental drug trial less than 30 days before screening\n* Patients have to be on a stable dosage of any medications used to treat muscle cramps for ≥30 days or have been off these medications ≥30 days prior to randomization.","ALL","18 Years",{"count":18,"type":19},72,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.",[25],"Amyotrophic Lateral Sclerosis",[27,28,29,30],"ALS","Motor Neuron Disease","Lou Gehrig's Disease","Placebo-Controlled","RECRUITING","2026-06-04",{"date":34,"type":35},"2026-06-08","ACTUAL",{"date":37,"type":35},"2025-04-29",{"date":39,"type":19},"2028-07",{"name":41,"class":42},"Swathy Chandrashekhar, MBBS","OTHER",6,""]